- Liraglutide, a glucagon-like peptide-1 analog, in individuals with obesity in clinical practice
-
Juyoung Shin, Raeun Kim, Hun-Sung Kim
-
Cardiovasc Prev Pharmacother. 2023;5(2):49-53. Published online April 28, 2023
-
DOI: https://doi.org/10.36011/cpp.2023.5.e7
-
-
3,084
View
-
63
Download
-
1
Citations
-
 Abstract
 PDF
- Obesity is a disease requiring treatment. The prevalence of obesity is steadily increasing both in Korea and worldwide. Individuals with obesity are at elevated risks of diabetes, cerebrovascular disease, and solid cancer; therefore, obesity is now considered to be a disease requiring treatment, rather than merely a cosmetic problem. Nutrition and exercise are the basic forms of obesity management, but it is not easy to lose weight through only one’s own willpower. Accordingly, policies for establishing a cultural environment that encourages desirable behaviors are proposed through multifaceted efforts involving the media and local organizations. However, the pharmacological and surgical treatments selected as medical interventions should be individualized based on an understanding of each individual’s cause of obesity and characteristics. It is important to understand how to enhance and maintain the effectiveness of treatment not only for the prescribing medical staff, but also for the individual with obesity who is being treated.
-
Citations
Citations to this article as recorded by  - Nonalcoholic fatty liver disease and heart failure with preserved ejection fraction: a focus on risk factors and management
Joonpyo Lee, Mi-Seung Shin
Cardiovascular Prevention and Pharmacotherapy.2025; 7(1): 1. CrossRef
|
